ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback